Blood Pressure Medication Recalled Over Critical Dosage Error
The Medicines and Healthcare Products Regulatory Agency (MHRA) has initiated an urgent recall for a specific batch of blood pressure medication following the discovery of a significant manufacturing error. This recall affects Ramipril 10mg capsules produced by Crescent Pharma Limited, where some packets may incorrectly contain blister strips of Ramipril 5mg capsules instead of the prescribed higher dosage.
Details of the Manufacturing Defect
The regulatory alert was triggered after a patient reported finding a blister pack of Ramipril 5mg capsules inside a sealed carton labelled as Ramipril 10mg. Both product batches were manufactured at the same facility, with the error occurring during the secondary packaging phase when cartons were assembled. The MHRA has identified the impacted batch as GR174091 and has advised all pharmacy and healthcare professionals to immediately cease supplying this batch and return any remaining stock to their suppliers.
Dr Alison Cave, the MHRA's chief safety officer, emphasised the importance of patient vigilance. "If you take Ramipril 10mg, check the packaging for batch number GR174091. The batch number and expiry date information can be found on the outer carton. If you have received this batch, verify that the medication name on the carton matches the blister strips inside," she stated.
Patient Safety and Risk Assessment
Despite the seriousness of the error, the MHRA has reassured the public that the health risk from taking a lower dose for a short period is very low. Ramipril is a widely prescribed medication used by millions globally to manage high blood pressure, heart failure, and kidney disease, and it is also administered after heart attacks to prevent further complications.
The medication functions by widening blood vessels, which facilitates easier blood pumping by the heart, thereby reducing the risk of strokes, heart attacks, and kidney problems. Both the 5mg and 10mg strengths are therapeutic for these conditions, though dosages are typically tailored individually.
- Starting doses usually range from 1.25mg to 2.5mg once daily to avoid dizziness.
- Dosages are gradually increased over several weeks, with maximum limits of 5mg twice daily or 10mg once daily.
- Any potential impact from a lower dose is expected to be gradual rather than immediate or life-threatening.
Recommended Actions for Patients
Patients who discover that their Ramipril 10mg carton contains blister strips labelled as Ramipril 5mg should contact their dispensing pharmacy promptly for guidance and replacement. However, if the blister strips are correctly labelled as Ramipril 10mg, no further action is necessary. Those experiencing adverse effects after taking the mispackaged lower doses are urged to seek medical advice, although such incidents are anticipated to be rare given the low risk profile.
This recall underscores the critical importance of stringent quality control in pharmaceutical manufacturing and highlights the proactive role of regulatory bodies in safeguarding public health. The MHRA continues to monitor the situation closely to ensure patient safety remains paramount.
